{"nctId":"NCT02059291","briefTitle":"Study of Efficacy and Safety of Canakinumab in Patients With Hereditary Periodic Fevers","startDateStruct":{"date":"2014-06-27","type":"ACTUAL"},"conditions":["Hereditary Periodic Fevers"],"count":203,"armGroups":[{"label":"crFMF: 150 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Canakinumab"]},{"label":"crCMF: placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]},{"label":"HIDS/MKD: 150 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Canakinumab"]},{"label":"HIDS/MKD: placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]},{"label":"TRAPS: 150 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Canakinumab"]},{"label":"TRAPS: placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Canakinumab","otherNames":["ACZ885"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria: - Patient's written informed consent (or parent's written informed consent in case of pediatric patient) at screening - Male and female patients at least 2 years of age at the time of the screening visit. Male and female patients \\>28 days but \\<2 years eligible for open label treatment only. - Confirmed diagnosis and active flare at randomization - CRP \\>10mg/L at randomization\n\nExclusion Criteria: - Use of the following therapies (within varying protocol defined timeframes): Corticosteroids, anakinra, canakinumab, rilonacept, tocilizumab, TNF inhibitors, abatacept, tofacitinib, rituximab, leflunomide, thalidomide, cyclosporine, intravenous immunoglobulin, 6-Merceptopurine, azathioprine, cyclophosphamide, or chlorambucil, any other investigational biologics - History of malignancy of any organ system (other than localized basal cell carcinoma of the skin or in - situ cervical cancer), treated or untreated - Significant medical diseases, including but not limited to the following: a. History of organ transplantation b. Elevated liver enzymes â‰¥3x ULN d. Increase in total bilirubin e. Serious hepatic disorder (Child-Pugh scores B or C) f. Chronic Kidney Disease g. Thyroid disease h. Diagnosis of active peptic ulcer disease i. Coagulopathy j. Significant CNS effects including vertigo and dizziness - Any conditions or significant medical problems which immunecompromise the patient and/or places the patient at unacceptable risk for immunomodulatory therapy - Live vaccinations within 3 months prior to the start of the trial, during the trial, and up to 3 months following the last dose","healthyVolunteers":false,"sex":"ALL","minimumAge":"1 Month","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Resolution of Initial Flare and Absence of New Flares up to the End of the Randomized Treatment Epoch (16 Weeks)","description":"Resolution of the initial disease flare is defined as: Physician's Global Assessment of Disease activity (PGA) \\<2 and C-reactive protein (CRP) within normal range (\\<= 10 mg/L) or reduction by at least 70% from baseline. The PGA was evaluated by the investigator based on a 5-point scale: 0 = None (no) disease associated with clinical signs and symptoms; 1 = minimal disease associated signs and symptoms; 2 = mild disease associated signs and symptoms; 3 = moderate disease associated signs and symptoms; and 5 = severe disease associated signs and symptoms.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"61.29","spread":null},{"groupId":"OG001","value":"6.25","spread":null},{"groupId":"OG002","value":"35.14","spread":null},{"groupId":"OG003","value":"5.71","spread":null},{"groupId":"OG004","value":"45.45","spread":null},{"groupId":"OG005","value":"8.33","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieve Physician's Global Assessment (PGA) < 2","description":"The PGA was evaluated by the investigator based on a 5-point scale: 0 = None (no) disease associated with clinical signs and symptoms; 1 = minimal disease associated signs and symptoms; 2 = mild disease associated signs and symptoms; 3 = moderate disease associated signs and symptoms; and 5 = severe disease associated signs and symptoms.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"64.52","spread":null},{"groupId":"OG001","value":"9.38","spread":null},{"groupId":"OG002","value":"45.95","spread":null},{"groupId":"OG003","value":"5.71","spread":null},{"groupId":"OG004","value":"45.45","spread":null},{"groupId":"OG005","value":"4.17","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With the Serologic Remission","description":"Serologic remission was defined as C-reactive protein \\<= 10 mg/L.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"67.74","spread":null},{"groupId":"OG001","value":"6.25","spread":null},{"groupId":"OG002","value":"40.54","spread":null},{"groupId":"OG003","value":"5.71","spread":null},{"groupId":"OG004","value":"36.36","spread":null},{"groupId":"OG005","value":"8.33","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Normalized Serum Amyloid A (SAA) Level","description":"Normalized SAA was defined as SAA \\<= 10 mg/L.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25.81","spread":null},{"groupId":"OG001","value":"0.00","spread":null},{"groupId":"OG002","value":"13.51","spread":null},{"groupId":"OG003","value":"2.86","spread":null},{"groupId":"OG004","value":"27.27","spread":null},{"groupId":"OG005","value":"0.00","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants of Canakinumab Responders From Epoch 2 Who Maintained a Clinically Meaningful Response (Absence of New Flares) (40 Weeks)","description":"A responder was defined as a participant who had no flare between week 16 and week 40.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"77.8","spread":null},{"groupId":"OG001","value":"30.0","spread":null},{"groupId":"OG002","value":"50.0","spread":null},{"groupId":"OG003","value":"14.3","spread":null},{"groupId":"OG004","value":"75.0","spread":null},{"groupId":"OG005","value":"40.0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":4},"commonTop":["Pyrexia","Headache","Abdominal pain","Upper respiratory tract infection","Diarrhoea"]}}}